STEM CELL THERAPY SUPERNOVA
We implant EMBRYONIC STEM CELLS from our STEM CELL BANK This is state-of-the-art ADVANTAGE for it eliminates the suffering and pain from liposuction(fat removal) or bone marrow extraction,...
By: Leong Lau
Read the original post:
STEM CELL THERAPY SUPERNOVA - Video
PUBLIC RELEASE DATE:
24-Jul-2014
Contact: David McKeon dmckeon@nyscf.org 212-365-7440 New York Stem Cell Foundation
NEW YORK, NY (July 24, 2014) Scientists at The New York Stem Cell Foundation (NYSCF) Research Institute are one step closer to creating a viable cell replacement therapy for multiple sclerosis from a patient's own cells.
For the first time, NYSCF scientists generated induced pluripotent stem (iPS) cells lines from skin samples of patients with primary progressive multiple sclerosis and further, they developed an accelerated protocol to induce these stem cells into becoming oligodendrocytes, the myelin-forming cells of the central nervous system implicated in multiple sclerosis and many other diseases.
Existing protocols for producing oligodendrocytes had taken almost half a year to produce, limiting the ability of researchers to conduct their research. This study has cut that time approximately in half, making the ability to utilize these cells in research much more feasible.
Stem cell lines and oligodendrocytes allow researchers to "turn back the clock" and observe how multiple sclerosis develops and progresses, potentially revealing the onset of the disease at a cellular level long before any symptoms are displayed. The improved protocol for deriving oligodendrocyte cells will also provide a platform for disease modeling, drug screening, and for replacing the damaged cells in the brain with healthy cells generated using this method.
"We are so close to finding new treatments and even cures for MS. The enhanced ability to derive the cells implicated in the disease will undoubtedly accelerate research for MS and many other diseases," said Susan L. Solomon, NYSCF Chief Executive Officer.
"We believe that this protocol will help the MS field and the larger scientific community to better understand human oligodendrocyte biology and the process of myelination. This is the first step towards very exciting studies: the ability to generate human oligodendrocytes in large amounts will serve as an unprecedented tool for developing remyelinating strategies and the study of patient-specific cells may shed light on intrinsic pathogenic mechanisms that lead to progressive MS". said Dr. Valentina Fossati, NYSCF Helmsley Investigator and senior author on the paper.
In multiple sclerosis, the protective covering of axons, called myelin, becomes damaged and lost. In this study, the scientists not only improved the protocol for making the myelin-forming cells but they showed that the oligodendrocytes derived from the skin of primary progressive patients are functional, and therefore able to form their own myelin when put into a mouse model. This is an initial step towards developing future autologous cell transplantation therapies in multiple sclerosis patients
Go here to read the rest:
NYSCF scientists one step closer to cell therapy for multiple sclerosis patients
San Diego, CA (PRWEB) July 25, 2014
WABC Radio show out of New York City, A Paws For Your Pet with Lorry Young will be hosting California-based Vet-Stem, Inc.s Founder and CEO, Robert J. Harman, DVM, to talk about stem cell therapy in pets. Dr. Harman first visited the show in November 2013 to discuss the benefits of stem cell therapy for pets suffering from osteoarthritis and other degenerative diseases, as well as recent developments moving the Regenerative Veterinary Medicine industry forward.
Young has invited Dr. Harman back to dial down into specific case studies and success stories of the over 10,000 dogs, cats, horses and exotic animals that Vet-Stems services have treated in the last decade. Moose, a Labrador Retriever Mix, is one of those special pet patients in the New York City area that was treated with Vet-Stem Regenerative Cell Therapy for arthritis caused by elbow dysplasia, and arthritic bone growth.
When Mooses owners noticed decreased mobility, lameness, and an increasingly lower tolerance for other dogs they brought Moose to local veterinarian Alex Klein to explore solutions. As many as 65% of dogs between the ages of 7 and 11 years old are inflicted with some degree of arthritis. Certain specific breeds, much like Moose, are reported to have as high of a percentage as 70 in being diagnosed with arthritis.
Stem cell therapy has been proven to help with the pain of arthritis in pets because it decreases inflammation, regenerates damaged tissues, and restores range of motion. An owner survey showed that greater than 80% of dogs treated for osteoarthritis in one or more leg joints with Vet-Stem Regenerative Cell Therapy showed an improved quality of life. Dogs like Moose have a small amount of fat collected by their veterinarian, which is sent overnight to Vet-Stems lab. There, the fat is separated from the stem cells and injectable doses of concentrated stem cells are sent back to the veterinarian overnight. Within 48 hours Moose received injections in his arthritic joints and the healing process began.
This ability to improve on a pets quality of life is why Dr. Harman is so passionate about sharing stories with other animal enthusiasts such as Young and her radio audience. Pet-spert, Young offers a special look into the latest techniques, treatments, and options that will enable listeners to provide their pets with a safer, healthier, and happier life. Produced and hosted by Young, A Paws For Your Pet, helps listeners answer any potential questions they may have regarding the health and well-being of their beloved pet, and hosts experts in the industry like Dr. Harman regularly.
About Vet-Stem, Inc. Since its formation in 2002, Vet-Stem, Inc. has endeavored to improve the lives of animals through regenerative medicine. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, Vet-Stem pioneered the use of regenerative stem cells for horses, dogs, cats, and some exotics. In 2004 the first horse was treated with Vet-Stem Regenerative Cell Therapy for a tendon injury that would normally have been career ending. Ten years later Vet-Stem celebrated its 10,000th animal treated, and the success of establishing stem cell therapy as a proven regenerative medicine for certain inflammatory, degenerative, and arthritic diseases. As animal advocates, veterinarians, veterinary technicians, and cell biologists, the team at Vet-Stem tasks themselves with the responsibility of discovering, refining, and bringing to market innovative medical therapies that utilize the bodys own healing and regenerative cells. For more information about Vet-Stem and Regenerative Veterinary Medicine visit http://www.vet-stem.com or call 858-748-2004.
Read this article:
Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode ...
stepping away from embryotic stem cells
stem cell research.
By: minh hoang
See the article here:
stepping away from embryotic stem cells - Video
Cord Blood Stem Cells Save Lives The Nucifora Story
Jeanette and David Nucifora have three daughters. There were all born at Credit Valley Hospital in Mississauga. At birth, they chose to save the cord blood stem cells for all three girls. This...
By: Cells for Life
Visit link:
Cord Blood Stem Cells Save Lives The Nucifora Story - Video
July 24, 2014, 10:29 p.m.
A 60 MINUTES report on new multiple sclerosis stem cell therapy has thrown Wendouree mum Kathryn Johnston a potential lifeline.
A 60 MINUTES report on new multiple sclerosis stem cell therapy has thrown Wendouree mum Kathryn Johnston a potential lifeline.
Hopeful: Wendouree mum Kathryn Johnston is hoping new stem cell therapy treatment will help her be a more active mother to her daughter Dellah, 7. PICTURE: KATE HEALY
Ms Johnston, who has had MS for 15 years, is hoping the treatment will help her be a more active mother to daughter Dellah, 7.
I cant do a great deal with my daughter now but its also the unknown not knowing if Ill wake up one day and not be able to walk, Ms Johnston said.
The 35-year-old emergency nurse hopes to travel to Russia in August next year for the treatment, which involves extracting her stem cells, freezing them while she undergoes a strong course of chemotherapy and then replacing them.
It gets rid of any underlying MS and rebuilds the immune system from scratch. As a general rule, its been about 80 per cent effective.
Ms Johnston first noticed her MS symptoms as an active Ararat 20-year-old doing her nursing degree and about to marry her childhood sweetheart Andrew.
I developed numbness in both hands but thought Id just slept on them until my tummy went numb too.
More here:
MS stem cell therapy treatment hope for mum
La Jolla, CA (PRWEB) July 23, 2014
StemGenex, the leading resource for adult adipose stem cell therapy in the US aimed at improving the lives of patients dealing with degenerative diseases today announced their newest clinical study for Parkinsons disease. StemGenex believes that a commitment to the safety and efficacy of stem cell therapy are paramount when providing care to patients with degenerative diseases.
This clinical study makes stem cell therapy accessible to the millions of individuals currently living with Parkinsons disease. The protocol used in these stem cell treatments is unique to StemGenex, having the possibility of being more effective than other stem cell treatments currently available. StemGenex has developed a multiple administration protocol for patients suffering from Parkinsons disease which includes targeted methods of stem cell delivery. Among these methods is a novel approach for delivering stem cells past the blood brain barrier an issue most stem cell treatments have been challenged by.
Principal Investigator Dr. Jeremiah McDole, Ph.D. stated, As is the case with most neurodegenerative conditions, there are few available drugs to treat Parkinsons disease. The handful of drugs that are available can only ameliorate symptoms and unfortunately, prolonged usage can create terrible side-effects. Further, these drugs do not halt disease progression or aid in the repair of established damage. Our goal is to provide regenerative medicine applications that address these critical issues. The study we are conducting is designed to provide us with a large amount of rigorously collected data so that we can better understand the clinical benefit of Parkinsons patients treated with stem cells.
This study is registered through The National Institutes of Health which can be found at http://www.clinicaltrials.gov and is being conducted under IRB approval. According to StemGenex Director of Patient Advocacy, Joe Perricone, It is important patients have access to top-tier stem cell therapy. By providing access to registered clinical studies through The National Institutes of Health, we are providing patients with the ability to choose a stem cell treatment center with the highest standard of care.
Rita Alexander, founder and president of StemGenex stated, Parkinson's disease affects a very small part of the brain but anyone suffering with this disease understands the negative impact on his or her life is very big, actually, enormous. Over the last several years we have observed significant improvement in the symptoms of Parkinsons patients through stem cell treatment. We are determined to be part of the solution and are eager to document and publish our findings in the next few years.
Stem cell treatment studies are currently being offered by StemGenex to patients diagnosed with Parkinsons disease and other degenerative neurological diseases. StemGenex takes a unique approach of compassion and empowerment while providing access to the latest stem cell therapies for degenerative neurological diseases including Multiple Sclerosis, Alzheimers disease, stroke recovery and others.
To find out more about stem cell therapy, contact StemGenex either by phone at (800) 609-7795 or email Contact(at)stemgenex(dot)com.
More here:
StemGenex Gives Hope to Parkinsons Patients through New Stem Cell Clinical Study
Dr Nathan Newman Stem Cell Technology by JEUNESSE
Dr. Nathan Newman explains the importance of Adult Stem Cells for looking younger, erasing wrinkles, healing acne and more. http://firstline.jeunesseglobal.com.
By: Jeunesse Global
Read the rest here:
Dr Nathan Newman Stem Cell Technology by JEUNESSE - Video
How to use stem cells? Luminesce Technology
By: Siriphat Chamnanvetch
Go here to read the rest:
How to use stem cells? Luminesce Technology - Video
"Stem Cells Dr. Nathan Newman" - Sean Wroe Jeuness Global Distributor
Stem Cells are the future of health and beauty. Jeunesse Global is at the forefront of this incredible Stem Cell Technology. Sean Wroe is a Jeunesse Global Distributor leading the way. http://www.seanwroe...
By: Sean Wroe
Originally posted here:
"Stem Cells Dr. Nathan Newman" - Sean Wroe Jeuness Global Distributor - Video
Scientists Find New Way To Make Human Platelets
Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Follow Follow Lauren Gores: http://www.twitter.com/laurengores...
By: NewsyVideos
Go here to see the original:
Scientists Find New Way To Make Human Platelets - Video
http://www.toothbank.com
Dental Stem Cell Banking. Secure your families future by storing your dental stem cells.
By: Jake Isenbarger
Go here to see the original:
http://www.toothbank.com - Video
A US Leader in Stem Cell Therapy - StemGenex
http://www.stemgenex.com/ - StemGenex offer patients access to cutting-edge adipose stem cell therapies for degenerative diseases, cosmetic enhancements and ...
By: EMSearch C
See the original post:
A US Leader in Stem Cell Therapy - StemGenex - Video
Los Angeles, CA (PRWEB) July 22, 2014
MetroMD, one of the leading names in regenerative medicines in all of California and one of the greatest proponents of holistic health services, now brings a reason to rejoice for individuals long suffering from debilitating arthritis. As per a report published on March 6 2013, by The Journal of Bone and Joint Surgery on The US National Library of Medicine National Institutes of Health (Ref: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3748969/), on an average, around 500,000 revision of knee replacement surgeries were recorded in the US - with the prime reason being osteoarthritis in majority of these cases. And If Mr. Devin Stone, MetroMDs Operations Director is to be believed, the cumulative cost of the treatment is estimated to be around $50 billion every year.
The cost covers hospitals bills, doctors visits, medicine, etc and makes arthritic treatment, which often requires a repeat procedure, a hugely burdensome endeavor. But the fact is, even after spending so much of money, one is not sure about getting fully relieved from the agony that arthritis brings to ones life. Arthritis appears in many forms and the expresses itself as joint pain, stiffness and limited body movement in a patient, says Dr Alex Martin, MD, MetroMDs Director of Medicines. MetroMD, ensures that patients can put aside all these concerns and enjoy complete healing that only an advanced Stem cell therapy for arthritis can promise, says Dr. Martin highlighting the fact regarding how pocket-friendly the treatment is. One can regain a healthy knee, while retaining the health of his/her money bag now with MetroMDs stem cell therapy.
How does MetroMDs Stem cell therapy Work?
MetroMDs stem cell treatment process includes extraction of healthy bone marrow out of the patients body by experts and placing it in a centrifuge. After segregating various elements of blood, the stem cell is isolated and placed with cellular growth promoters (found in platelets). All of these are then inserted into the part of the body, ensuring a quicker tissue-based healing.
Mr. Devin Stone exuded confidence in mentioning that MetroMDs stem cell therapies come as a great alternative to invasive surgeries - making way for easier and quicker knee replacements and arthritic treatment.
Is the stem cell therapy safe?
Dr. Alex Martin says, If you are suffering from chronic joint paint due to arthritis, surgery is not anymore the only answer. Stem Cell Therapy can provide an amazing alternative, where your own cells are used to promote healing inside your body. Medicine has advanced significantly in the last 15 years and persistence with the techniques that were pioneered over two decades ago is illogical- and newer and less invasive procedures are the future of medicine.
Backed by the fact that stem cell treatment is a minimally invasive procedure requiring little or no hospitalization, Dr Martins and MetroMDs stance towards propagating stem cell therapy looks only logical. The procedure is legal and the therapy rendered by MetroMD is in compliance with CFR 21 part 1271 standards. Being a non surgical process, evidently, its the safest and totally side-effect free process.
Dr. Martin welcomes the residents of LA suffering from debilitating arthritic condition to consult an expert at its branches spread across in several parts of Los Angeles - and enjoy an improved quality of life.
Continue reading here:
Arthritis Alleviated: MetroMD Introduces Latest in Stem Cell Therapy in LA; Promises to be Especially Helpful for ...
Hello Doctor Nandani Gokulchandran On Stem Cell Therapy Treatment 20th July 2014
By: zee chovis taas
View post:
Hello Doctor Nandani Gokulchandran On Stem Cell Therapy Treatment 20th July 2014 - Video
ViaCyte, a privately held regenerative medicine company developing a cell replacement therapy for the treatment of diabetes, has filed an Investigational New Drug application with the United States Food and Drug Administration, seeking to start a Phase 1/2 clinical trial in patients with type 1 diabetes, it was reported on Friday.
The trial will assess the safety and efficacy of ViaCyte's VC-01 product candidate, a stem cell-derived, encapsulated cell replacement therapy. The company has also submitted a Medical Device Master File to the United States Food and Drug Administration in support of the Encaptra drug delivery system, the device component of the VC-01 product candidate. The company's VC-01 product candidate includes pancreatic progenitor cells, called PEC-01 cells, which are derived from a proprietary human embryonic stem cell line.
Paul Laikind, Ph.D., president and chief executive officer of ViaCyte, said, 'The filing of this IND represents the culmination of many years of research and development by a dedicated team focused on developing a cell replacement therapy for patients with type 1 diabetes and advancing our VC-01 product candidate to human clinical trials. The ViaCyte team has been assisted and supported by the California Institute for Regenerative Medicine (CIRM) a leading organisation focused on advancing the field of stem cell-based technologies, and JDRF, the leading advocacy organisation for patients with type 1 diabetes.'
(C)2014 M2 COMMUNICATIONS http://www.m2.com
Get our daily newsletter or follow us.
Please enter your email below:
The rest is here:
ViaCyte asks FDA for go-ahead with human trials of cell replacement therapy for diabetes
Published 18 July 2014
ViaCyte a privately held regenerative medicine company developing a cell replacement therapy for the treatment of diabetes, announced that it has filed an Investigational New Drug application (IND) with the United States Food and Drug Administration (FDA) seeking to initiate a Phase 1/2 clinical trial in patients with type 1 diabetes.
The trial would evaluate the safety and efficacy of ViaCyte's VC-01 product candidate, a stem cell-derived, encapsulated cell replacement therapy. In a related development, ViaCyte submitted a Medical Device Master File (called MAF) to the FDA in support of the Encaptra drug delivery system, the device component of the VC-01 product candidate.
"The filing of this IND represents the culmination of many years of research and development by a dedicated team focused on developing a cell replacement therapy for patients with type 1 diabetes and advancing our VC-01 product candidate to human clinical trials," said Paul Laikind, Ph.D., President and Chief Executive Officer of ViaCyte. "The ViaCyte team has been assisted and supported by the California Institute for Regenerative Medicine (CIRM) a leading organization focused on advancing the field of stem cell-based technologies, and JDRF, the leading advocacy organization for patients with type 1 diabetes," added Dr. Laikind.
ViaCyte's VC-01 product candidate consists of pancreatic progenitor cells, called PEC-01 cells, which are derived from a proprietary human embryonic stem cell line. These cells are then encapsulated by use of ViaCyte's Encaptra device. When implanted under the skin, the PEC-01 cells are designed to mature and further differentiate into insulin-producing beta and other endocrine cells that regulate blood glucose in a manner similar or identical to the normal islets that comprise the endocrine pancreas.
Based on a pre-IND meeting with the FDA and subsequent consultations, ViaCyte is proposing to initiate clinical evaluation of the VC-01 product candidate directly in patients with type 1 diabetes who have minimal to no insulin-producing beta cell function. In addition to evaluating the safety of the product candidate in these patients, the study is designed to demonstrate the effectiveness of the VC-01 product candidate in replacing lost endocrine function that is central to the disease.
In the proposed clinical trial, insulin production from the VC-01 implant would be assessed by measuring C-peptide, a biomarker for insulin produced by beta cells that is expected to provide a sensitive measure of efficacy in these patients. As proposed, the trial would also evaluate secondary end-points related to the need for administration of pharmaceutical insulin to control the disease and the incidence of hypoglycemia, a common side effect associated with pharmaceutical insulin usage.
ViaCyte's proprietary Encaptra device is designed to contain the implanted cells, preventing biodistribution, as well as shielding them from the immune system. Although PEC-01 cells are human cells, they are not the patient's actual cells. As such, they are considered an allogeneic graft, which typically requires immunosuppression in order for the recipient to tolerate the implant. However, the Encaptra device is designed to prevent the patient's immune system from accessing the implanted cells, thereby facilitating successful engraftment and subsequent maturation to islets.
The VC-01 product candidate is designed to be placed under the skin of the patient and can be monitored and readily removed, if or when required. The option to remove the cells is designed to provide an important safety benefit for this novel stem cell-derived cell therapy candidate. It is being regulated as a biologic through interaction with the Office of Cell, Tissue and Gene Therapy within CBER at the FDA. Given the combination product nature of the product candidate, the Center for Devices and Radiological Health at the FDA is also involved in its regulation.
The rest is here:
ViaCyte files investigational new drug application and device master file with FDA for novel cell replacement therapy ...
TRAGIC STORY! Paid $25,000 for Stem Cells @ Hospital Angeles Tijuana http://www.RegenerativeMedicine.mx
TWO Websites: http://www.regenerativemedicinemx.com AND http://www.regenerativemedicinetijuana.com STEM CELL Resources: http://www.cellmedicinesociety.org/component/content/article/86-news/410-mex...
By: KyaLarae
See the original post here:
TRAGIC STORY! Paid $25,000 for Stem Cells @ Hospital Angeles Tijuana http://www.RegenerativeMedicine.mx - Video
Stem Cell Therapy in Cardiac Disease - Charles Murry, MD, Ph.D.
How can we harness the power of stem cells to repair the heart or other damaged organs? Dr. Chuck Murry, Dept. of Pathology; Director, Center for Cardiovascular Biology at the University of...
By: UWTV
See the article here:
Stem Cell Therapy in Cardiac Disease - Charles Murry, MD, Ph.D. - Video
Common shoulder conditions treated with stem cell therapy
In this video, Ross Hauser, MD discusses the types of shoulder conditions our Prolotherapy team specializes in treating with stem cell therapy and platelet rich plasma Prolotherapy. If you...
By: Caring Medical and Rehabilitation Services
View original post here:
Common shoulder conditions treated with stem cell therapy - Video